According to research published in the Journal of Investigative Dermatology, the amyopathic dermatomyositis discomfort may be lessened by using lenabasum, a cannabinoid receptor type 2 (CB2) agonist. Dermatomyositis is a rare systemic autoimmune disease with distinctive cutaneous features frequently accompanied by muscle inflammation, interstitial lung disease, and malignancy. The potential advantages of stimulating the endocannabinoid system to lessen the inflammation producing the symptoms were investigated in this phase 2 experiment. Twenty-two adults who had dermatomyositis, a moderate to severe skin condition, were study participants. They received 20 mg daily of lenabasum or a placebo for 28 days, then 20 mg twice daily for 56 days. Their Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) levels were evaluated relative to baseline as well as secondary outcomes.